A review and expert opinion of the use of certolizumab for Crohn's disease

Expert Opinion on Biological Therapy

Volumn 12, Issue 3, 2012, Pages 363-370

  Evans, Ashley T ^a   Lee, Scott D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biological therapy; Certolizumab pegol; Crohn's disease; Inflammatory bowel disease; TNF inhibitor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; CONGENITAL DISORDER; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; FETUS WASTAGE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LOW BIRTH WEIGHT; LYMPHOMA; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PREMATURE LABOR; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; EXPERT TESTIMONY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS;

EID: 84863144401     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.658770     Document Type: Review

References (32)

1. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohns disease and ulcerative colitis in Olmsted County, Minnesota, 1940 -2000. Inflamm Bowel Dis 2007;13:254-61 (Pubitemid 46465905)
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohns disease. Inflamm Bowel Dis 2002;8:244-50 (Pubitemid 34784976)
3. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohns disease. Gastroenterology 2006;130:650-6
4. Mekhjian HS, Switz DM, Melnyk CS, et al. Clinical features and natural history of Crohns disease. Gastroenterology 1979;77:898-906 (Pubitemid 9257853)
5. Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohns disease. Aliment Pharmacol Ther 2009;29:605-14
6. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32 (Pubitemid 350206841)
7. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91
8. Scherl E, Bosny P-L, Lee S. Formation of autoantibodies in patients with moderate to severe Crohns disease, receiving continuous and interrupted CZP therapy with or without concomitant immunosuppressants. In American College of Gastroenterology 2011 abstracts; Washington DC
9. Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43 (Pubitemid 34717741)
10. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for the treatment of Crohns disease. N Engl J Med 2007;357:228-38 (Pubitemid 47080387)
11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohns disease. N Engl J Med 2007;357:239-50 (Pubitemid 47080388)
12. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohns disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82
13. Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohns disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702; e1
14. Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohns disease -subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185-93
15. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease. Gastroenterology 2010;138:463-8; quiz e10-11
16. Colombel JF, Lemann M, Bouhnik Y, et al. Endoscopic mucosal improvement in patients with active crohns disease. treated with certolizumab pegol: week 10 and 54 results of the music trial [abstract]. Gastroenterology 2010;138(5 Suppl 1):S-166
17. Sandborn WJ, Abreu MT, DHaens G, et al. Certolizumab pegol in patients with moderate to severe Crohns disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95 e2.
18. Lichtenstein GR, Thomsen OØ, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohns disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9
19. Lacroix BD, Parker GL. Dosing with certolizumab pegol (CZP) 200 mg every 2 weeks (Q2w) provides higher plasma trough concentrations than 400 mg every 4 weeks (Q4w). Gastroenterology 2010;138(Supp 1):S163-4
20. Lee SD, Ko C, Wahbeh G, et al. Assessment of the Efficacy of Certolizumab Pegol for the Treatment of Crohns Disease at a Single North American Center, in American College of Gastroenterology2010: San Antonio, TX. Available from: http://www.uwgi.org/news/acg2010-P1132.pdf [Last acccessed 17 January 2012]
21. Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohns disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85
22. Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohns disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
23. Certolizumab Pegol. 10/2011; 9/2011. Brussels, Belgium: UCB 2011. Available from: http://www.cimzia.com/pdf/Prescribing-Information.pdf [Last accessed 17 January 2012]
24. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133:1106-12 (Pubitemid 47494456)
25. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14:1736-50
26. Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood. Arthritis Rheum 2010;62(Suppl 10):718
27. Porter C, Kopotsha T, Smith BJ, et al. No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro (abstract). Ann Rheum Dis 2010;69(Suppl 3):210
28. Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994;1:667-9 (Pubitemid 2164290)
29. Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero., in Digestive Disease Week (DDW)2011: Chicago, IL. Avaialable from: http://www.ddw.org/user-assets/documents/PDF/05-press/11/ DDW%202011% 20Drugs%20Abstracts.pdf [Last accessed 17 January 2012]
30. Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohns disease. Aliment Pharmacol Ther 2010;32:384-93
31. Vavricka SR, Schoepfer AM, Bansky G, et al. Efficacy and safety of certolizumab pegol in an unselected Crohns disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2011;17:1530-9
32. Schoepfer AM, Vavricka SR, Binek J, et al. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohns disease population: results of the FACTS survey. Inflamm Bowel Dis 2010;16:933-8